Replies to post #40284 on Cel Sci Corporation (CVM)

[BRMachine]

The company targeted H&N first because of an unmet need. The plan is to test on other cancers after approval for H&N. There is already some data (phase I or pre-clinical) on effectiveness for other cancers.

[drkazmd65]

We're only talking about H&N cancer at this point because that's where the clinical trial actually has generated data.

It is quite likely (assuming that CVM does get FDA approval for H&N treatments) that other, similar types of cancer will start to get either treated off label, or even might get their own clinical trials. IMO - it's also likely that a similar improvement will be seen once that work is done.

By that time CVM will likely be generating a steady stream of revenue (again,... assuming H&N FDA approval) and can write their own (and our own) tickets for these studies, or license out making Multikine and focus the company on developing the LEAPS system further.